ABSTRACT

Background: Micronutrients play an important role in the human immune system. During HIV infection, the virus utilises the micronutrients of the body, for its replication causing metabolic disorders including phosphocalcic. Parathyroid hormone (PTH), vitamin D₃ (25-hydroxyvitamin D₃) and calcitonin are essential for the maintenance of phosphocalcic homeostasis and the proper functioning of the body. In Côte d’Ivoire, very few studies on HIV infection and the mechanism of phosphocalcic metabolism have been done. The purpose of this study was to determine the status of 25 (OH) D₃ and parathyroid hormone in people living with HIV.
Methodology: The study involved 326 adults (163 HIV-positive and 163 HIV-negative as control subjects). After confirmation by HIV serologic scanning result, CD4 count was performed by flow cytometry (Facs Calibur). Assays for 25 (OH) D₃ and PTH were performed by HPLC and COBAS 6000 automated systems, respectively.

Results: A decrease in mean values of 25 (OH) D₃ (16 ± 0.46 ng / mL) was observed in 50% of HIV-infected on ART and 87% of these patients presented a normal PTH level (28 ± 1.95 pg / mL). Deficiency of 25 (OH) D₃ (20 ± 1.03 ng / mL) is higher in HIV-infected on ART who have a CD4 count < 200 cells / mL.

Conclusion: Parathyroid hormone levels were normal in this study. Insufficiency or deficiency of 25-hydroxyvitamin D₃ is more common in HIV-infected on ART with a CD4 count < 200 cells / mL. This decrease characterized the degree of immunodepression.

Keywords: 25-hydroxyvitamin D₃; ART; Côte d'Ivoire; HIV; parathyroid hormone.

ABBREVIATIONS

PTH : Parathyroid hormone
CYP27B1 : Cytochrome 27 B1
cART : Combined antiretroviral therapy
EDTA : Ethylene diamine tetra acetic
PLHIV : People living with HIV
FGF-23 : Fibroblast Growth Factor 23
VDR : Vitamin D Receptor
cAMP : Cyclic Adenosine monophosphate

1. INTRODUCTION

Human immunodeficiency virus (HIV) infection is pandemic affecting 33.3 million people worldwide. In 2015, 1.1 million deaths and 2.1 million new HIV infections were recorded [1]. Sub-Saharan Africa remains severely affected by this pandemic and accounted for about 70% of new HIV infections [2]. In Côte d'Ivoire, the prevalence rate reduced from 3.4% in 2012 to 2.7% in 2016 [3].

During HIV infection, the virus uses nutrients, including micronutrients of the body, for replication [4]. This causes disorders of mineral metabolism, including phosphocalcic [5,6]. The regulation of calcium and phosphorus homeostasis involves parathyroid hormone (PTH), vitamin D₃ (25-hydroxyvitamin D₃) and calcitonin [7]. PTH is secreted in the parathyroid glands. It is a hypercalcemic hormone. In case of hypocalcaemia, parathyroid hormone facilitates mobilization of bone calcium, stimulates the activation of vitamin D₃ in the kidneys, which in turn increases, the intestinal absorption of calcium, while inhibiting its excretion in the urine [8]. Vitamin D₃ is a circulating steroid hormone that exists in the human body in two forms: 25 (OH) D₃, a form of reserve that under the action of 1-α-hydroxylase or CYP27B1 renal, hydroxylated to 1,25-dihydroxyvitamin D₃ (1,25 (OH)₂D₃), its active form [9]. Its main role is the regulation of calcium and phosphate homeostasis [10]. It also controls cell proliferation and differentiation [11].

Concerning HIV treatment, combined antiretroviral therapy (cART) does not eradicate HIV, which persists for years and can re-establish replication if treatment is stopped [12]. cART expose HIV-infected patients to chronic adverse effects, including neurocognitive disorders, cardiovascular and metabolic diseases, kidney and bone diseases (osteopenia / osteoporosis) and cancer [13].

In Côte d'Ivoire, few studies about the mechanism of regulation of phosphocalcic homeostasis in HIV-positive Ivorian patients have been undertaken [6]. The main objective of this study was therefore to determine the 25-hydroxyvitamin D₃ and parathyroid status of HIV-positive patients.

2. MATERIALS AND METHODS

2.1 Type of Study

This is a cross-sectional descriptive study conducted from November 2015 to December 2016 at the Department of Fundamental Biochemistry and Medical at Institut Pasteur of Côte d'Ivoire (IPCI).

2.2 Biological and Technical Material

A collection of fasting venous blood samples from 326 adult subjects (163 HIV-positive patients and 163 HIV-negative controls) was obtained for the various biochemical and serological tests. HIV-positive pregnant women
were not included in this study. Thus, a blood tube containing EDTA (Thermo, Tokyo, Japan) was used for the determination of CD4 + T cell count (whole blood) of HIV-positive subjects. A blood tube without anticoagulant (dry tubes) was used for HIV serological tests and biochemical parameters. Finally, the blood glucose assay was performed in serum from tube containing potassium oxalate and sodium fluoride.

Two rapid serological tests were performed for the detection of anti-HIV antibodies: the Alere Determine™ HIV-1/2 immunochromatographic kit whose principle is based on the formation of an antigen-antibody complex revealed after staining [14] and the SD Bioline HIV-1/2 3.0 immunoenzymatic confirmation test based on the detection of anti-HIV1 and anti-HIV2 antibodies specifically directed against antigens [15].

2.3 Biochemical Parameters

The CD4 + T lymphocyte count was performed in flow cytometry on the Facs Calibur from whole blood collected in EDTA [16]. The assay of 25-hydroxyvitamin D₃ is carried out using UV detection in high performance liquid chromatography (HPLC) with a Waters® device, after extraction of soluble vitamins with hexane in the dark protected from the light according to the method described by Zaman et al. [17]. The parathyroid hormone assay, based on electrochemiluminescence detection, was performed on COBAS 6000 [18]. Assay of biochemical parameters such as Creatinine, Urea, Blood glucose, Alanine aminotransferase, Calcium, Phosphorus, Magnesium and Alkaline phosphatase was performed on COBAS C311 HITACHI. The principle is based on enzymatic and colorimetric methods that use a chromogen. The intensity of the observed coloration is directly proportional to the concentration of the substance assayed [19].

2.4 Statistical Analyses

The statistical analyses were performed using the Graphpad Prism Demo 5 software. The ANOVA test, followed by the Turkey test, were used to calculate and compare the averages. The degree of significance has been set at 5%.

2.5 Ethical Considerations

The study was conducted in accordance with the Helsinki 2000 Declaration on HIV and AIDS Research in Poor Countries and in accordance with local legislation on the National Program for the Care of People Living with HIV / AIDS (Decree No. 411 of 23 December 2001). Furthermore, for the research, consent was obtained from individuals for the use of their blood samples collected during biological monitoring.

3. RESULTS AND DISCUSSION

3.1 Characteristics of the Study Population

The average age of the study population is 39 years for treated people living with HIV (PLHIV) and 32 years for untreated PLHIV with extremes of 18 to 49 years. The mean age of the control was 31 years with extremes of 18 to 49 years (Table 1).

3.2 Biochemical Profile of the Study Population

Among the biochemical parameters analysed (Calcium, Phosphorus, Magnesium, Alkaline Phosphatases, Alanine aminotransferase, Glycemia, Creatinine, Urea), only phosphorus was significantly higher in treated PLHIV (2.55 ± 0.37, $P<0.0001$) and in untreated PLHIV (1.97 ± 0.25, $P<0.0001$) than in controls (1.19 ± 0.03). The other values were in the range of the reference values (Table 1).

3.3 Vitamin D and Parathyroid Status of the Study Population

In this study, a deficiency (< 20 ng/mL) of 25-hydroxyvitamin D₃ was observed in 12% (19/163) of HIV-negative controls, 50% (60/120) in PLHIV on ART and 12% (5/43) in PLHIV without ART. Similarly, insufficiency (20-30 ng/mL) of 25-hydroxyvitamin D₃ was noted in 44% (72/163) of the controls, 33% (40/120) of the PLHIV under ART and 42% (18/43) PLHIV without ART. Finally, normal mean values (≥ 30 ng/mL) of 25-OH vitamin D₃ were obtained in 44% (72/163) of controls, 33% (40/120) of the PLHIV under ART and 42% (18/43) PLHIV without ART. Regarding PTH level, only 10% (12/120) of PLHIV on ART experienced hypoparathyroidism (<10 pg/mL). Table 2 also shows a normal level (10.85 pg/mL) of PTH in 96% (157/163) of HIV-negative controls and in almost all PLHIV without ART (100%, 43/43). Hyperparathyroidism was observed in 4% (6/163) of HIV-negative controls compared to 3% (4/120) of PLHIV on ART.
3.4 Vitamin D and Parathyroid Status According to CD4 T cell Level

In patients without ART, a decrease in mean values of 25-OH vitamin D$_3$ according to the degree of immunodepression was observed. However, in patients on triple therapy, mean 25-OH vitamin D$_3$ concentrations are within the normal range for CD4 + T cell count greater than 500 cells/mL (32 ± 2.41 ng/mL) and those between 349 - 200 cells / mL (31 ± 2.29 ng/mL). However, a 25-hydroxyvitamin D$_3$ deficiency was found in CD4 + T cell count between 499 - 350 cells / mL (23 ± 1.14 ng/mL) and below 200 cells / mL (20 ± 1.03 ng/mL) (Fig. 2a). As for parathyroid hormone, concentrations were normal for all CD4 + T cell count and the presence or absence of ART (Fig. 1b).

The population affected by HIV infection is young, more sexually active and economically active [20]. In Spain, an average age of 37 years has been reported [21]. A similar study conducted with a population aged 18 to 60 found an average age of 36 years [22].

The primary function of 25 (OH) D is the regulation of calcium and phosphate homeostasis [10]. In this our study, calcium levels are normal, however we observed hyperphosphatemia in all HIV-infected individuals. This confirms the disruption of phosphocalcic balance reported by Boyvin et al. [6]. This situation is thought to be due to vitamin D deficiency [23] as observed in this study among PLHIV. The hyperphosphatemia is thought to be due to a low serum concentration of parathyroid hormone (PTH) and the inhibitory action of FGF-23 on α1-hydroxylase. As a result, there will be no phosphate reabsorption in the proximal tubule [24]. The hyperphosphatemia observed in some PLHIV could also be due to the release of phosphorus into the bloodstream after bone resorption [25]. Thus, a direct effect of HIV on osteogenic cells has been reported, persistent activation of pro-inflammatory cytokines, upregulation of TNF-alpha that induces apoptosis in the osteoblast model [26].

In addition, although HIV-infected patients in this study had serum creatinine levels within normal range, subclinical renal dysfunction affecting homeostasis [10]. In this our study, calcium phosphocalcic balance reported by Boyvin et al. [6]; Article no.AJRB.41385 confirms the disruption of phosphocalcic balance observed by Boyvin et al. [6]. This situation is thought to be due to vitamin D deficiency [23] as observed in this study among PLHIV. The hyperphosphatemia in all HIV-infected patients is, therefore, due to vitamin D deficiency [23] as observed in this study.

3.5 Vitamin D and Parathyroid Status According to Age

In the 18-25 age group, untreated patients have a normal 25 (OH) D$_3$ concentrations (27 ± 0.56 ng/mL) but high when compared to controls and treated patients (16 ± 0.66 ng/mL). However, the control populations have 25 (OH) D$_3$ deficiency, whereas the treated patients have deficiency in 25 (OH) D$_3$ (Fig. 2a). For parathyroid hormone, mean concentrations were normal but slightly higher in treated patients (20 ± 1.47 pg/mL) than in controls (19 ± 1.02 pg/mL) and in patients without treatment (16 ± 0.73 pg/mL) (Fig. 2b).

The population affected by HIV infection is young, more sexually active and economically active [20]. In Spain, an average age of 37 years has been reported [21]. A similar study conducted with a population aged 18 to 60 found an average age of 36 years [22].

In the 26-34 age group, treated patients and untreated patients showed 25 (OH) D$_3$ deficiency respectively (29 ± 2.98 ng/mL; 26 ± 0.67 ng/mL) compared to controls (31 ± 1.05 ng/mL) (Fig. 2a). In contrast, concentrations of PTH were lower (7 ± 0.56 pg/mL) in treated patients than in controls (26 ± 2.28 pg/mL) but normal in untreated patients (30 ± 2.27 pg/mL) (Fig. 2b).

In the 35-49 age group, 25 (OH) D$_3$ deficiency was observed in treated patients (24 ± 1.84 ng/mL) compared to controls (31 ± 1.99 ng/mL). 25 (OH) D$_3$ levels were normal in untreated patients (34 ± 2.42 ng/mL) (Fig. 2a). PTH mean values in controls (29 ± 3.35 pg/mL), treated patients (28 ± 2.39 pg/mL) and untreated patients (28 ± 2.45 pg/mL) were in the range of normal reference values (Fig. 2b).

In this study, the average ages are 38 years for treated PLHIV and 31 years for untreated PLHIV. The population affected by HIV infection is young, more sexually active and economically active [20]. In Spain, an average age of 37 years has been reported [21]. A similar study conducted with a population aged 18 to 60 found an average age of 36 years [22].

In conclusion, untreated PLHIV have a deficiency of 25 (OH) D$_3$ in 50% of treated PLHIV and approximately 12% of untreated PLHIV. These results are similar to those of Ansemant et al.[29] who reported a deficiency of 25 (OH) D$_3$ in 50% of treated PLHIV. Similarly, a deficiency was observed in approximately 12% of HIV negative controls and insufficiency in 44% of controls. Sufficiency in 25 (OH) vitamin D reserves observed in our study could be explained due to the fact that Côte d'Ivoire is a tropical country with heavy sunshine, the major intakes pathway of vitamin D is through...
Table 1. Mean values of biological parameters of the study population

| Parameters                  | Control (N=163) | Treated patients (N=120) | Untreated patients (N=43) | P value a  | P value b  | P value c  |
|-----------------------------|-----------------|--------------------------|---------------------------|------------|------------|------------|
| Age (years)                 | 31 ± 0.67       | 39 ± 0.63                | 32 ± 1.23                 | < 0.0001*  | 0.3169     | < 0.0001*  |
| Alkaline Phosphatase (40 – 129 UI/L) | 77 ± 1.75       | 122±16.84                | 100 ± 5.18                | 0.0026*    | < 0.0001*  | 0.2954     |
| Calcium (2.2 – 2.7 mmol/L)  | 2.5± 0.04       | 2.9 ± 0.04               | 2.7  ± 0.04               | < 0.0001*  | 0.0163*    | 0.0030*    |
| Phosphorus (0.90 – 1.45 mmol/L) | 1.19±0.03       | 2.55±0.37                | 1.97 ± 0.25               | < 0.0001*  | < 0.0001*  | 0.1948     |
| Magnesium (0.65 – 1.15 mmol/L) | 0.78±0.01       | 0.86±0.01                | 0.78 ± 0.02               | < 0.0001*  | 0.6594     | 0.0002*    |
| Alanine aminotransferase (7 - 48 UI/L) | 17 ± 1.00       | 23 ± 1.63                | 18 ± 0.83                 | 0.0031*    | 0.8027     | 0.0171*    |
| Glycemia (4.16 - 6.11 mmol/L) | 5.00 ± 0.11     | 4.95±0.05                | 4.84 ± 0.11               | 0.8279     | 0.5521     | 0.4240     |
| Creatinine (53 - 106 µmol/L) | 70.8±1.59       | 70.8± 2.30               | 70.8 ± 2.74               | 0.6113     | 0.6653     | 0.4389     |
| Urea (1.66 - 5.83 mmol/L)   | 4.65 ± 0.17     | 4.48±0.33                | 3.82 ± 0.33               | 0.4652     | 0.0065*    | 0.1772     |

a: Control versus treated Patients; b: Control versus untreated Patients; c: Treated Patients versus Untreated Patients; * P denotes statistically significant value; The difference is significant for P< 0.05

Table 2. Distribution of the study population according to 25 (OH) D₃ and parathyroid hormone status

| Parameters                  | Control (N=163) | Treated Patients (N=120) | Untreated patients (N=43) |
|-----------------------------|-----------------|--------------------------|---------------------------|
| **25 (OH) D₃**              |                 |                          |                           |
| Deficiency < 20 ng/mL       | 19 (12 %)       | 60 (50 %)                | 5 (12 %)                  |
| Insufficiency 20 - 30 ng/mL | 72 (44 %)       | 40 (33 %)                | 18 (42 %)                 |
| Sufficiency≥ 30 ng/mL       | 72 (44 %)       | 20 (17 %)                | 20 (46 %)                 |
| **Parathyroid hormone**     |                 |                          |                           |
| Insufficiency < 10 pg/mL    | 0 (0 %)         | 12 (10 %)                | 7 ± 0.21                  |
| Normal 10 - 65 pg/mL        | 157(96 %)       | 104 (87 %)               | 43 (100 %)                |
| Elevated > 65 pg/mL         | 6 (4 %)         | 4 (3 %)                  | 0 (0 %)                   |

Normal reference value of 25 (OH) D₃: 30 – 100 ng/mL
Fig. 1. 25 (OH) D$_3$ (a) and PTH (b) status according to CD4+ count

Fig. 2. 25 (OH) D$_3$ (a) and PTH (b) status according to ages

skin synthesis [30,31]. But the deficiency cases observed in control subjects may be due to the consumption of diets poor in vitamin D or other factors, since its supply has two sources (food and synthesis) [32]. Hypovitaminosis D is a global disorder, with a high prevalence in the population from the developing and western countries [33]. Beyond genetic, racial, geographic and seasonal differences, this deficiency is thought to be due to insufficient consumption of foods containing vitamin D (e.g. milk and dairy products, fish, eggs and enriched orange juice) [34]. Furthermore, other factors such as female sex, age, dark skin pigmentation, body mass index (BMI), gastrointestinal absorption disorders -intestinal, risk factors for multiple cardiovascular diseases, including diabetes mellitus, co-infections including HIV / tuberculosis (TB), HIV / hepatitis C virus (HCV), renal and/or hepatic pathologies such as cholestatic hepatitis and current alcohol consumption are cited as risk factors for traditional hypovitaminosis D in seropositive and seronegative cohorts [13]. According to studies, even healthy people, exposed to adequate sunlight, can’t synthesize enough vitamin D without supplementation [35,36]. Moreover, 25 (OH) D$_3$ insufficiency was found in 33% of treated PLHIV and 42% of untreated PLHIV. Gichuhi et al. [37] also found 25 (OH) D$_3$ insufficiency in 32.78% of treated PLHIV and 35.09% of untreated PLHIV. Indeed, in case of advanced HIV infection, a proinflammatory state is observed. Certain cytokines (INF-Υ, IL-4) which are then secreted interact with cytochrome CYP27B1 which is a catalyst for renal 1α-hydroxylase [38]. This study showed insufficiency and deficiency in 25 (OH) D$_3$ in
treated PLHIV, in the range of CD4 T cell count of 499 - 350 cells / mL and less than 200 cells / mL respectively.

In this range of CD4, the occurrence of opportunistic infections highly increases the production of pro-inflammatory cytokines including TNF alpha (Tumor Necrosis Factor alpha) which inhibit 1-alpha -hydroxylase at the renal level thus stopping the transformation of 25 (OH) 2 vitamin D into its active form 1-25 (OH) vitamin D [39]. But also antiretroviral drugs especially IP and INNTI are highly inhibitory of cytochrome P450 and 25- and 1-alpha-hydroxylase enzymes [40]. Indeed, vitamin D is essential for maintaining phosphocalcic homeostasis. It also exhibits an immune defense regulatory activity and the ability to modulate the differentiation and proliferation of certain cell types that expresses the vitamin D receptor (VDR).

Untreated patients also showed insufficiency in 25 (OH) D3 in the CD4 + T cell count range of less than 200 cells / mL. In general, in this range of CD4 T cells, infectious complications resulting from poor immunity require hospital care, which significantly reduces the duration of sun exposure for patients. Moreover, these infectious complications and hospitalization can lead to malnutrition and decreased oral consumption of certain foods containing vitamin D [13].

Therefore, this deficiency or insufficiency of vitamin D would disrupt immune system function and response. It would precipitate the destruction of CD4 and the progression of the disease [41]. Other authors have also found a positive association between vitamin D and CD4 counts [42]. In addition, deficiency in circulating vitamin D3 could also be explained by variations in the locus encoding Vitamin D Receptor (VDR) during HIV infection [43]. VDR dysfunction related to 25 (OH) D3 deficiency [44] is associated with progression of HIV infection [43,45].

In the present study, hypoparathyroidism (< 10 pg/mL) was observed only in 10 % (12/120) of treated patients. It should be noted that a decrease in the rate of PTH has already been reported in HIV infected patients [46]. The mechanism could be related to antibodies against parathyroid cells. Using anti-Leu3a, a monoclonal antibody that recognizes CD4, it has been found that HIV-positive patients have a CD4 molecule on the surface of parathyroid cells, indicating the possibility of functional inhibition by antibody anti-CD4 or direct HIV infection [47]. In addition, TNF-α appears to interfere with the stimulatory effect of PTH by mechanisms involving downregulation of PTH receptors, alteration of protein kinase C activity, and inhibition of cAMP response after PTH stimulation [23]. In addition, hyperparathyroidism was observed in 3% (4/120) of treated PLHIV against 4% (6/163) in HIV- negative controls. Studies have indicated that even a slight reduction in 25 (OH) D3 serum levels may be associated with secondary hyperparathyroidism, increased bone renewal, and accelerated bone loss. This increases the risk of bone fractures [48]. In this study, the level of PTH is normal in all ranges of CD4 + T cells count in both treated and untreated patients. Although a high PTH concentration is considered characteristic of hypovitaminosis D, a "normal" concentration of PTH can be found in subjects classified as "vitamin D deficient". Therefore, although many subjects with 25 (OH) D3 serum levels below the threshold may have PTH in the "normal" reference range, they may have "functional hyperparathyroidism" [49]. Thus, hypovitaminosis D may be considered a major risk factor for bone health [50].

5. CONCLUSION

This study showed that parathyroid hormone levels were normal in the population. They could not therefore be involved in phosphocalcic balance disruption. Furthermore, 25 (OH) D3 deficiency was more common in treated patients, especially those with CD4 counts below 200 cells / mm³ and age range 18-25 years. This disruption of 25 (OH) D3 could be due to insufficient dietary intake of vitamin D-rich foods and not a parathyroid hormone-related defect. Deficiency of 25 (OH) D3 could also be due to dysfunction of the vitamin D nuclear receptor (VDR). It would be interesting to further study the nuclear receptor of vitamin D (VDR).

ETHICAL APPROVAL

The study was conducted in accordance with the Helsinki 2000 Declaration on HIV and AIDS Research in Poor Countries and in accordance with local legislation on the National Program for the Care of People Living with HIV/AIDS (Decree No. 411 of 23 December 2001). Furthermore, for the research, consent was obtained from individuals for the use of their blood samples collected during biological monitoring.
COMPETING INTERESTS

Authors have declared that no competing interests exist.

REFERENCES

1. WHO. Global health sector strategy on HIV 2016-2021. Geneva 27 Switzerland. WHO/HIV/2016.05; 2017. (Accessed 14 October 2017) Available: http://www.who.int/hiv/strategy2016-2021/ghs-hiv/en/

2. UNAIDS. Global report epidemiology slides, in core epidemiology slides, Geneva. World Health Organization. 2013; 274. (Accessed 11 September 2015) Available: http://www.unaids.org/en/resources/documents/2017/20170720_CoRe_ Epidemiology_slides

3. UNAIDS. Country fact sheets Côte d’Ivoire 2016: HIV and AIDS Estimates; 2016. (Accessed 14 October 2017) Available: http://www.unaids.org/fr/regions/countries/countries/ctedi

4. Shin DH, Martinez SS, Parsons M, Jayaweera DT, Campa A, Baum MK. Relationship of oxidative stress with HIV disease progression in HIV/HCV Co-infected and HIV mono-infected adults in Miami. Intern J Biosci Biochem Bioinform. 2012;2:217-23.

5. Marco B, Davide G, Fabio V, Elisa D, Laura C, Carlo B, et al. Metabolic bone disease in HIV infection. Editorial Review. 2009;23:1297-1310.

6. Boyvin L, Aké JA, Séri KL, M’Boh GM, Yapo AF, Djaman JA. 25 (OH) Vitamin D level and calcium/phosphorus metabolism disorders in patients living with HIV in Abidjan. Int J Biochem Res Rev. 2017; 17(4);1-7.

7. Milovanova L, Milovanov Y, Plotnikova A. Phosphorus and calcium metabolism disorders associated with chronic kidney disease stage III-IV (Systematic review and meta-analysis). In Tech. 2012;95-119.

8. Michels TC, Kelly KM. Parathyroid disorders. American Family Physician. 2013;88(4):249-57.

9. Carlberg C, Seuter S, De Mello VDF, Schwab U, Voutilainen S, Pulkkı K, et al. Primary vitamin D target genes allow a categorization of possible benefits of vitamin D3 supplementation. Plos One. 2013;8:1-7.

10. Schuch NJ, Garcia VC, Vivolo SRF, Martini LA. Relationship between Vitamin D receptor gene polymorphisms and the components of metabolic syndrome. J Nutr. 2013;12:1-96.

11. Chaves HL, Moreira HP, Corrêa HAH, Machado WBO, Teles RB, Nascimento LR, et al. Vitamin D and secondary hyperparathyroidism in HIV infected patients taking antiretroviral therapy. World Journal of AIDS. 2014;4:310-37.

12. Nolan DJ, Rose R, Rodriguez PH, Salemi M, Singer EJ, Lamers SL, et al. The spleen is an HIV-1 sanctuary during combined antiretroviral therapy. AIDS Research and Human Retroviruses. 2018;34(1):123-25.

13. Mansueto P, Seidita A, Vitale G, Gangemi S, Iaria C, Cascio A. Vitamin D deficiency in HIV infection: Not only a bone disorder. Biomed Res Int. 2015. Article ID 735615.

14. Crucitti T, Taylor D, Beelaert G, Fransen K, Damme LV. Performance of a rapid and simple HIV testing algorithm in a multicenter phase III microbicidal clinical trial. Clin. Vaccine Immunol. 2011;18(9):1480–1485.

15. Sagar NA, Sen M, Yadav VK. Serodiagnosis of HIV by rapid test and ELISA test assay in a tertiary care centre in Northern India. Int J Curr Microbiol App Sci. 2015;4(10):623-29.

16. Ormerod MG, Imrie PR. Flow cytometry, USA, ed. Human Press; 1990.

17. Zaman Z, Fielden P, Frost PG. Simultaneous determination of vitamins A and E and carotenoids in plasma by reversed-phase HPLC in elderly and younger subjects. Clin Chem. 1993;39:2229-2234.

18. Souberbielle JC, Brazier F, Piketty ML, Cormier C, Minisola S, Cavalier E. How the reference values for serum parathyroid hormone concentration are (or should be) established? J Endocrinol Invest. 2016; 1-16.

19. Deyhimi F, Arabieh M, ParvinL. Optimization of the Emerson–trinder enzymatic reaction by response surface methodology. Biocatalysis and Bio Transformation. 2006;24:263-71.

20. Boyvin L, M’Boh G, Ake-Edjeme A, Soumahoro-Agbo MK, Séri KL, Djaman J. Serum level of two antioxidant vitamins (A and E) in Ivorian (Côte d’Ivoire) people living with human immunodeficiency virus.
Annals of Biological Research. 2013;4(11): 48-4.

21. Luis DA, Bachiller P, Aller R, de Luis J, Izaola O, Terroba MC, et al. Relation among micronutrient intakes with CD4 count in HIV infected patients. Nutrition. 2002;17:285-89.

22. Ademasu A, Kerisew B, Nibret E, Munshea A, Adal M. Serum Zinc Deficiency and associated factors among preart and on-ART adults at Felegehiwot referral hospital, Bahir Dar, Northwest Ethiopia. Int J Nutr Food Sci. 2014;3:311-17.

23. Haug CJ, Aukrust P, Haug E, Mkørked L, Müller F, Froland SS. Severe deficiency of 1,25-dihydroxyvitamin D3 in human immunodeficiency virus infection: Association with immunological hyperactivity and only minor changes in calcium homeostasis. J Clin Endocrinol Metab. 1998;83 (11):3832-3838.

24. Moges B, Amare B, Yabutani T, Kassu A. HIV associated hypocalcemia among diarrheic patients in northwest Ethiopia: A cross-sectional study. BMC Public Health. 2014;14:679. DOI: 10.1186/1471-2458-14-679

25. Indridason OS, Quares LD. Hyperphosphatemia in end-stage renal disease. Adv Ren Replace Ther. 2002; 9(3):184-92.

26. Brown TT, Qaqish RB. Antiretroviral therapy and the prevalence of osteopenia and osteoporosis: A meta-analytic review. AIDS. 2006;20:2165-2174.

27. Sai AJ, Walters RW, Fang X, Gallagher JC. Relationship between vitamin D, parathyroid hormone and bone health. J Clin Endocrinol Metab. 2011;96(3):1-11.

28. Hileman CO, Overton ET, Mc Comsey GA. Vitamin D and bone loss in HIV. Curr Opin HIV AIDS. 2016;11(3):277–84.

29. Ansemant M, Mahy S, Piroth C, Ornetti P, Ewing S, Guillard JCl, et al. Severe hypovitaminosis D correlates with increased inflammatory markers in HIV infected patients. BMC Infectious Diseases. 2013;13(7):1-7.

30. Kim JH, Gandhi V, Psevdos GJR, Espinoza F, Park J, Sharp V. Evaluation of vitamin D levels among HIV-infected patients in New York City. AIDS Res Hum Retroviruses. 2012;28:235-241.

31. Norval M, Coussens AK, Wilkinson RJ, Bonnman L, Lucas RM, Wright CY. Vitamin D status and its consequences for health in South Africa. Int J Environ Res Public Health. 2016;13(10):1019. DOI: 10.3390/ijerph13101019 20

32. Dougherty KA, Schall JI, Zemel BS, Tuluc F, Hou X, Rutstein RM, et al. Safety and efficacy of high-dose daily vitamin D3 supplementation in children and young adults infected with human immunodeficiency virus. J Pediatric Infect Dis Soc. 2014;3(4):294-303.

33. Arabi A, EI Rassi R, El-Hajj FG. Hypovitaminosis D in developing countries—prevalence, risk factors and outcomes. Nat Rev Endocrinol. 2010;6: 550-61.

34. Holick MF. Vitamin D deficiency. N Engl J Med. 2007;357:266-81.

35. Mangin M, Sinha R, Fincher K. Inflammation and vitamin D: The infection connection. Inflamm. Res. Inflammation Research. 2014;63:803-19.

36. Coussens AK, Naude CE, Goliath R, Chaplin G, Wilkinson RJ, Jablonski NG. High-dose vitamin D3 reduces deficiency caused by low UVB exposure and limits HIV-1 replication in urban Southern Africans. Proc Natl Acad Sci USA. 2015; 112(26):8052-8057.

37. Gichuhi CW, Kariuki D, Nyerere A, RiyatM. Studies on Vitamin D levels in serum of HIV infected patients: Their effect on progression towards AIDS. World Journal of AIDS. 2014;4:422-29.

38. White J. Regulation of intracrine production of 1,25-dihydroxyvitamin D and its role in innate immune defense against infection. Arch Biochem Biophys. 2012; 523:58-3.

39. Conesa-Botella A, Mathieu C, Colebunders R, Moreno-Reyes R, Van Etten E, Lynen L, et al. Is vitamin D deficiency involved in the immune reconstitution inflammatory syndrome? AIDS Res Ther. 2009;21:6:4. DOI: 10.1186/1742-6405-64

40. Conesa-Botella A, Florence E, Lynen L, Colebunders R, Menten J, Moreno-Reyes R. Decrease of vitamin D concentration in patients with HIV infection on a non nucleoside reverse transcriptase inhibitor-containing regimen. AIDS Res Ther. 2010;7:40.

41. Stein EM, Yin MT, McMahon DJ, Shu A, Zhang CA, Ferris DC, et al. Vitamin D deficiency in HIV-infected postmenopausal
Hispanic and African-American women. Osteoporos Int. 2011;22(2):477-87.

43. Kim JH, Gandhi V, Psevdos Jr. G, Espinoza F, Park J, Sharp V. Evaluation of vitamin D levels among HIV-infected patients in New York City. AIDS Research and Human Retroviruses. 2011;28:235-41.

44. Nieto G, Barber Y, Rubio MC, Rubio M, Fibla J. Association between AIDS disease progression rates and the Fok-I polymorphism of the VDR gene in a cohort of HIV-1 seropositive patients. J Steroid Biochem. 2004;89(90):199-07.

45. Waterhouse JC, Perez TH, Albert PJ. Reversing bacteria-induced 25-hydroxyvitamin D receptor dysfunction is key to autoimmune disease. Ann NY Acad Sci. 2009;1173:757-65.

46. Sánchez de la Torre M, Torres C, Nieto G, Vergara S, Carrero AJ, Macías J, Pineda JA, Caruz A, Fibla J. Vitamin D receptor gene haplotypes and susceptibility to HIV-1 infection in injection drug users. J Infect Dis. 2008;197:405-10.

47. Cherqaoui R, Shakir KMM, Shokrani B, Madduri S, Farhat F, Mody V. Histopathological changes of the thyroid and parathyroid glands in HIV-infected patients. Journal of Thyroid Research. 2014;7. DOI: org/10.1155/2014/364146

48. Hellman P, Karlsson-Parra A, Klareskog L, Ridefelt P, Björneroth G, Rastad J, et al. Expression and function of a CD4-like molecule in parathyroid tissue. Surgery. 1996;120:985-92.

49. Adams JS, Hewison M. Update in vitamin D. J Clin Endocrinol Metab. 2010;95:471-78.

50. Okazaki R, Sugimoto T, Kaji H, et al. Vitamin D insufficiency defined by serum 25-hydroxyvitamin D and parathyroid hormone before and after oral vitamin D3 load in Japanese subjects. J Bone Miner Metab. 2011;29:103-10.

51. Mori H, Okada Y, Tanaka Y. Incidence of Vitamin D deficiency and its relevance to bone metabolism in Japanese postmenopausal women with type 2 diabetes mellitus. Intern Med. 2015;54:1599-1604.

© 2018 Aké et al.; This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Peer-review history:
The peer review history for this paper can be accessed here:
http://www.sciencedomain.org/review-history/24370